Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia

BMC Musculoskelet Disord. 2019 Sep 4;20(1):402. doi: 10.1186/s12891-019-2767-x.

Abstract

Background: The lower limb joints, including hip and knee, are the most commonly involved joints in haemophilic arthropathy. With a higher risk of transfusion, total hip and knee arthroplasty (THA and TKA) are still the first choice after failure of conservative treatment. In the present study, we aimed to analyze clinical outcomes and complications rate after total joint arthroplasty of the lower limbs using tranexamic acid (TXA) or not.

Methods: Thirty-four patients with haemophilia A undergoing 24 TKA and 18 THA were evaluated in this retrospective study (No. 201302009). Based on using TXA or not, they were divided into either TXA (12 knees and 10 hips) or Non-TXA groups (12 knees and 8 hips). Total blood loss, intraoperative blood loss, total amount of FVIII usage, range of motion, inflammatory biomarkers, joint function, pain status, complication rate and patient satisfaction were assessed and compared at a mean follow-up of 68 months.

Results: Usage of TXA can decrease not only the perioperative blood loss (p = 0.001), transfusion rate (p = 0.017) and supplemental amount of FVIII (p < 0.001) but also swelling ratio, surgical joint pain. Moreover, compared with non-TXA group, the patients in TXA group had a lower level of inflammatory biomarkers and better joint function.

Conclusion: The hemophiliacs treated with TXA had less perioperative blood loss, hidden blood loss, transfusion rate, a lower ratio of postoperative knee swelling, less postoperative joint pain, lower levels of inflammatory biomarkers and better joint function. Further studies need performing to assess the long-term effects of TXA in these patients.

Keywords: Blood loss; Hip; Knee; Total joint arthroplasty; Tranexamic acid; Transfusion.

MeSH terms

  • Administration, Intravenous
  • Adult
  • Antifibrinolytic Agents / administration & dosage*
  • Antifibrinolytic Agents / adverse effects
  • Arthralgia / epidemiology
  • Arthralgia / etiology
  • Arthralgia / prevention & control
  • Arthroplasty, Replacement, Hip / adverse effects*
  • Arthroplasty, Replacement, Knee / adverse effects*
  • Blood Loss, Surgical / prevention & control
  • Blood Loss, Surgical / statistics & numerical data
  • Blood Transfusion / statistics & numerical data
  • Factor VIII / administration & dosage
  • Female
  • Hemophilia A / complications*
  • Hemophilia A / diagnosis
  • Hemophilia A / drug therapy
  • Hip Joint / physiology
  • Hip Joint / surgery
  • Humans
  • Knee Joint / physiology
  • Knee Joint / surgery
  • Male
  • Middle Aged
  • Osteoarthritis, Hip / complications
  • Osteoarthritis, Hip / physiopathology
  • Osteoarthritis, Hip / surgery
  • Osteoarthritis, Knee / complications
  • Osteoarthritis, Knee / physiopathology
  • Osteoarthritis, Knee / surgery
  • Pain, Postoperative / epidemiology
  • Pain, Postoperative / etiology
  • Pain, Postoperative / prevention & control
  • Postoperative Hemorrhage / epidemiology
  • Postoperative Hemorrhage / etiology
  • Postoperative Hemorrhage / prevention & control
  • Preoperative Care / methods
  • Prospective Studies
  • Range of Motion, Articular
  • Recovery of Function
  • Retrospective Studies
  • Tranexamic Acid / administration & dosage*
  • Tranexamic Acid / adverse effects
  • Treatment Outcome

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid
  • Factor VIII